巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Macrophage Inflammatory Protein 1 Alpha (MIP1a) ,etc. by FLIA (Flow Luminescence Immunoassay)
CCL3; MIP1-A; SCYA3; Chemokine C-C-Motif Ligand 3; Small Inducible Cytokine A3; Homologous To Mouse Mip-1a; Tonsillar Lymphocyte LD78 Alpha Protein
(注:單次混測多因子不超過8個指標 )
- 編號LMA092Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍0.98-1000pg/mL
- 靈敏度最小可檢測劑量小于等于0.327 pg/mL.
- 樣本類型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標數(shù) 7指標數(shù) 6指標數(shù) 5指標數(shù) 4指標數(shù) 3指標數(shù) 2指標數(shù)1指標數(shù)
- 價格 ¥ 2090 ¥ 2171 ¥ 2291 ¥ 2452 ¥ 2613 ¥ 2854 ¥ 3216 計算器 ¥ 4020 添加到價格計算器
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標樣品),重復(fù)測定并計算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 79-94 | 89 |
EDTA plasma(n=5) | 93-101 | 96 |
heparin plasma(n=5) | 89-101 | 96 |
sodium citrate plasma(n=5) | 78-98 | 94 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對低、中、高值定值樣本進行定量檢測,每份樣本連續(xù)測定20 次,分別計算不同濃度樣本的平均值及SD值。
批間差:選取3個不同批次的試劑盒分別對低、中、高值定值樣本進行定量測定,每個樣本使用同一試劑盒重復(fù)測定8次,分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-96% | 98-105% | 86-104% | 93-102% |
EDTA plasma(n=5) | 93-101% | 91-105% | 91-99% | 99-105% |
heparin plasma(n=5) | 88-103% | 89-102% | 80-103% | 91-99% |
sodium citrate plasma(n=5) | 83-91% | 83-90% | 92-101% | 98-105% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響,實驗室的環(huán)境條件需盡量保持一致,尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進行操作可減少人為誤差。
實驗流程
1. 實驗前標準品、試劑及樣本準備;
2. 加樣(標準品、樣本、磁珠)標準品或樣本100μL及磁珠10μL,
37°C酶標板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標準品或標本以及磁珠,其中的巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標記的親和素,再次徹底洗滌后即可上機讀數(shù)。MFI值和樣品中的巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
編號 | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA092Hu01 | 巨噬細胞炎性蛋白1α(MIP1a)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA092Hu01 | 巨噬細胞炎性蛋白1α(MIP1a)活性蛋白 | Cell?culture;?Activity?Assays. |
APA092Hu61 | 巨噬細胞炎性蛋白1α(MIP1a)活性蛋白 | Cell?culture;?Activity?Assays. |
EPA092Hu61 | 巨噬細胞炎性蛋白1α(MIP1a)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPA092Hu51 | 巨噬細胞炎性蛋白1α(MIP1a)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA092Hu07 | 巨噬細胞炎性蛋白1α(MIP1a)多克隆抗體 | WB; IHC; ICC; IP. |
PAA092Hu01 | 巨噬細胞炎性蛋白1α(MIP1a)多克隆抗體 | WB; IHC; ICC; IP. |
PAA092Hu06 | 巨噬細胞炎性蛋白1α(MIP1a)多克隆抗體 | WB; IHC; ICC; IP. |
MAA092Hu22 | 巨噬細胞炎性蛋白1α(MIP1a)單克隆抗體 | WB; IHC; ICC; IP. |
SEA092Hu | 巨噬細胞炎性蛋白1α(MIP1a)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCA092Hu | 巨噬細胞炎性蛋白1α(MIP1a)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMA092Hu | 巨噬細胞炎性蛋白1α(MIP1a)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA092Hu01 | 巨噬細胞炎性蛋白1α(MIP1a)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
PGA092Hu01 | 巨噬細胞炎性蛋白1α(MIP1a)引物對 | PCR |
參考文獻
雜志 | 參考文獻 |
Inhalation Toxicology | Age influence on hypersensitivity pneumonitis induced in mice by exposure to Pantoea agglomerans [Pubmed: 24044680] |
Scientific Reports | The Transcriptional Foundations of Sp110-mediated Macrophage (RAW264. 7) Resistance to Mycobacterium tuberculosis H37Ra [Pubmed:26912204] |
ActaMedicaMediterranea | CIRCULATING MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (MIP1-Α) AS A POTENTIAL BIOMARKER FOR THE DIAGNOSIS OF PATIENTS WITH … [57e97ac908aeb34bc08fd41a.pdf] |
National Natural Scientific | Role of Gut-Derived Endotoxin on Type I Collagen Production in the Rat Pancreas after Chronic Alcohol Exposure [pubmed:29121396] |
Pharmacological Reports | Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder [10.1016/j.pharep.2017.08.008] |
NPG?Asia?Materials | Molybdenum disulfide/graphene oxide nanocomposites show favorable lung targeting and enhanced drug loading/tumor-killing efficacy with improved?… [Articles:am2017225] |
Journal of Immunology?Research | Therapeutic Potential of Pien Tze Huang on Experimental Autoimmune Encephalomyelitis Rat [Pubmed:29682587] |
Journal of Immunology?Research | Cathelicidin LL-37 affects surface and intracellular Toll-like receptor expression in tissue mast cells [Pubmed:29670923] |
Pharmacological Reports | Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without?… [Pubmed:29339257] |
Journal?of?Food?Science | CQPC06 Activity Prevents Dextran Sulfate Sodium‐Induced Colitis by Regulating the IL‐8 Pathway [Doi: 10.1111/1750-3841.14346] |
Biochemical and Biophysical Research Communications | The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion [Pubmed: 30558792] |
LIFE SCIENCES | Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress [Pubmed: 33227274] |
ACTA PHARMACOLOGICA SINICA | α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice [Pubmed: 32973325] |
Life Sci | PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape [Pubmed: 32971102] |
Nature Communications | A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy [Pubmed: 32332752] |
Neoplasia | PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1 [34325342] |